Ethosuximide

Wyllie's Treatment of Epilepsy: Principles and Practice: Fifth Edition

Volumn , Issue , 2012, Pages 657-667

  Kanner, Andres M ^a,b,c   Glauser, Tracy A ^d,e   Morita, Diego A ^d,e  

^a RUSH MEDICAL COLLEGE   (United States)

^b Laboratory of EEG and Video EEG Telemetry   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80051667704     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (176)

1. Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms and management. Clin Neurophysiol. 2006;35:337-343.
2. Brodie M, Dichter M. Established antiepileptic drugs. Seizure. 1997;6:159-174.
3. Lennox W. The petit mal epilepsies: their treatment with tridione. JAMA. 1945;129:1069-1074.
4. Lennox W. Tridione in the treatment of epilepsy. JAMA. 1947;134:138-143.
5. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia. 1995;36:S13-S26.
6. Rogawski M, Porter R. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental state compounds. Pharmacol Rev. 1990;42:223-286.
7. Sabers A, Dam M. Ethosuximide and methsuximide. In: Shorvon S, Dreifuss F, Fish D, et al., eds. The Treatment of Epilepsy. London: Blackwell Science; 1996:414-420.
8. Bromfield E. Ethosuximide and other succinimides. In: Engel J, Pedley T, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott-Raven; 1997:1503-1508.
9. Millership JS, Mifsud J, Collier PS. The metabolism of ethosuximide. Eur J Drug Metab Pharmacokinet. 1993;18:349-353.
10. Pisani F, Meir B. Ethosuximide: chemistry and biotransformation. In: Levy R, Mattson R, Meldrum B, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995:655-658.
11. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40:S2-S10.
12. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1993;34:S1-S8.
13. Davies JA. Mechanisms of action of antiepileptic drugs. Seizure. 1995;4:267-271.
14. Coulter C, Huguenard J, Price D. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989;25:582-593.
15. Marescaux C, Vergnes M, Depaulis A. Genetic absence epilepsy in rats from Strasbourg: a review. J NeuralTransm Suppl. 1992;35:37-69.
16. Manning J-PA, Richards DA, Leresche N, et al. Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience. 2004;123:5-9.
17. Goren MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev. 2007;13:224-239.
18. Terzioglu B, Aypak C, Onat F, et al. The effects of ethosuximide on amino acids in genetic absence epilepsy rat model. J Pharmacol Sci. 2006;100: 227-233.
19. Richards DA, Manning J-PA, Barnes D. Targeting thalamic nuclei is not sufficient for the full anti-absence action of ethosuximide in a rat model of absence epilepsy. Epilepsy Res. 2003;54:97-107.
20. Tan HO, Reid CA, Single FN, et al. Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy. Proc Natl Acad Sci U S A. 2007;104:17536-17541.
21. Ferrendelli J, Holland K. Ethosuximide, mechanisms of action. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic drugs. 3rd ed. New York: Raven Press; 1989:653-661.
22. Lin-Mitchell E, Chweh A. Effects of ethosuximide alone and in combination with gamma-aminobutyric acid receptor antagonists on brain gamma-aminobutyric acid concentration, anticonvulsant activity, and neurotoxicity in mice. J Pharmacol Exp Ther. 1986;237:486-489.
23. Gilbert J, Buchan P, Scott A. Effects of anticonvulsant drug on monosaccharide transport and membrane ATPase activities of cerebral cortex. In: Harris P, Mawdsley C, eds. Epilepsy. Edinburgh: Churchill Livingstone; 1974:98-104.
24. Gilbert J, Scott A, Wyllie M. Effects of ethosuximide on adenosine triphosphate activities of some subcellular fractions prepared from rat cerebral cortex. Br J Pharmacol. 1974;50:452P-453P.
25. Gilbert J, Wyllie M. The effects of the anticonvulsant ethosuximide on adenosine triphosphatase activities of synaptosomes prepared from rat cerebral cortex. Br J Pharmacol. 1974;52:139P-140P.
26. Crunelli V, Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat RevNeurosci. 2002;3:371-382.
27. Kobayashi T, Ikedaq K. G protein-activated inwardly rectifying potassium channels as potential therapeutic targets. Curr Pharm Des. 2006;12:4513-4523.
28. Villen T, Bertilsson L, Sjoqvist F. Nonstereoselective disposition of ethosuximide in humans. Ther Drug Monit. 1990;12:514-516.
29. Tomson T, Villen T. Ethosuximide enantiomers in pregnancy and lactation. Ther Drug Monit. 1994;16:621-623.
30. El-Sayed M, Loscher W, Frey H. Pharmacokinetics of ethosuximide in the dog. Arch Int Pharmacodyn Ther. 1978;234:180-192.
31. Patel I, Levy R, Bauer T. Pharmacokinetic properties of ethosuximide in monkeys. Single dose intravenous and oral administration. Epilepsia. 1975;16:705-716.
32. Patel I, Levy R. Pharmacokinetic properties of ethosuximide in monkeys, II: chronic intravenous and oral administration. Epilepsia. 1975;16:717-730.
33. Patel I, Levy R, Rapport R. Distribution characteristics of ethosuximide in discrete areas of rat brain. Epilepsia. 1977;18:533-541.
34. Bialer M, Ziadong S, Perucca E. Ethosuximide: absorption, distribution, excretion. In: Levy R, Mattson R, Meldrum B, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press; 1995:659-665.
35. Chang T. Ethosuximide: absorption, distribution, and excretion. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989:671-678.
36. Buchanan R, Fernandez L, Kinkel A. Absorption and elimination of ethosuximide in children. J Clin Pharmacol. 1969;7:213-218.
37. Eadie M, Tyrer J, Smith J, et al. Pharmacokinetics of drugs used for petit mal absence epilepsy. Clin Exp Neurol. 1977;14:172-183.
38. Alvarez N, Besag F, Iivanainen M. Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res. 1998;42:1-15.
39. Wallace SJ. Use of ethosuximide and valproate in the treatment of epilepsy. Neurol Clin. 1986;4:601-616.
40. Chang T, Dill W, Glazko A. Ethosuximide: absorption, distribution and excretion. In: Woodbury D, Penry J, Schmidt R, eds. Antiepileptic Drugs. New York: Raven Press; 1972:417-423.
41. Loscher W, Frey H. Kinetics of penetration of common anticonvulsant drugs in serum of dog and man. Epilepsia. 1984;25:346-352.
42. Aguilar-Veiga E, Sierra-Paredes G, Galan-Valiente J, et al. Correlations between ethosuximide brain levels measured by high performance liquid chromatography and its antiepileptic potential. Res Comm Chem Pathol Pharmacol. 1991;7:351-364.
43. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet. 1999;36:453-470.
44. Buchanan R, Kinkel A, Smith T. The absorption and excretion of ethosuximide. Int J Clin Pharmacol. 1973;7:213-218.
45. Horning M, Brown L, Nowlin J, et al. Use of saliva in therapeutic drug monitoring. Clin Chem. 1977;23:157-164.
46. Piredda S, Monaco F. Ethosuximide in tears, saliva and cerebral fluid. Ther Drug Monit. 1981;3:321-323.
47. McAuliffe J, Sherwin A, Leppik I, et al. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology. 1977;27:409-413.
48. Van H. Comparative study of the levels of anticonvulsants and their free fraction in venous blood, saliva and capillary blood in man. J Pharmacol. 1984;15:27-35.
49. Bachmann K, Schwartz J, Sullivan T, et al. Single sample estimate of ethosuximide clearance. Int J Clin Pharmacol Ther Toxicol. 1986;24:546-550.
50. Meyer F, Quednow B, Potrafki A, et al. Pharmacokinetics of anticonvulsants in the perinatal period. Zentralbe Gynakol. 1988;110:1195-1205.
51. Horning M, Stratton C, Nowlin J, et al. Metabolism of 2-ethyl-2-methyl-succinimide in the rat and human. Drug Metab Dispos. 1973;1:569-576.
52. Koup J, Rose J, Cohen M. Ethosuximide pharmacokinetics in a pregnant patient and her newborn. Epilepsia. 1978;19:535-539.
53. Kaneko S, Sato T, Suzuki K. The levels of anticonvulsants in breast milk. Br J Clin Pharmacol. 1979;7:624-627.
54. Kuhnz W, Koch S, Hartmann A, et al. Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status. Br J Clin Pharmacol. 1984;18:671-677.
55. Hancock E, Osborne J, Milner P. Treatment of infantile spasms. Cochrane Database Syst Rev. 2003:CD001770.
56. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776-789.
57. Bachmann K, Jahn D, Yang C, et al. Ethosuximide disposition kinetics in rats. Xenobiotica. 1988;18:373-380.
58. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharmacol Ther. 1999;24:87-92.
59. Burkett A, Chang T, Glazko A. A hydroxylated metabolite of ethosuximide (Zarontin) in rat urine. Fed Proc. 1971;30:391.
60. Bachmann K. The use of single sample clearance estimates to probe hepatic drug metabolism in rats, IV: a model for possible application to phenotyping xenobiotic influences on human drug metabolism. Xenobiotica. 1989;19:1449-1459.
61. Bachmann K, Madhira M, Rankin G. The effects of cobalt chloride, SKF-525A and N-(3,5-dichlorophenyl) succinimide on in vivo hepatic mixed function oxidase activity as determined by single-sample plasma clearances. Xenobiotica. 1992;22:27-31.
62. Bachmann K, Chu C, Greear V. In vivo evidence that ethosuximide is a substrate for cytochrome P450IIIA. Pharmacology. 1992;45:121-128.
63. Chang T. Ethosuximide. Biotransformation. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989:679-683.
64. Patel I, Levy R, Bauer T. Time dependent kinetics, II: diurnal oscillations in steady state plasma ethosuximide levels in rhesus monkeys. J Pharm Sci. 1977;66:650-653.
65. Eadie MJ. Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance. Biomed Chromatogr. 1991;5:212-215.
66. Bachmann K, He Y, Sarver JG, et al. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003;33:265-276.
67. Gilbert J, Scott A, Galloway D, et al. Ethosuximide: liver enzyme induction and D-glucaric acid excretion. Br J Clin Pharmacol. 1974;1:249-252.
68. Glazko A. Antiepileptic drugs: biotransformation, metabolism, and serum half-life. Epilepsia. 1975;16:376-391.
69. Bauer L, Harris C, Wilensky A, et al. Ethosuximide kinetics: possible interaction with valproic acid. Clin Pharmacol Ther. 1982;31:741-745.
70. Buchanan R, Kinkel A, Turner J, et al. Ethosuximide dosage regimens. Clin Pharmacol Ther. 1976;19:143-147.
71. Dill W, Peterson L, Chang T, et al. Physiologic disposition of alpha-methyl-alpha-ethyl succinimide (ethosuximide; Zarontin) in animals and in man. Presented at the 149th National Meeting of the American Chemical Society; 1965; Detroit, MI.
72. Pisani P, Narbone M, Trunfio C. Valproic acid-ethosuximide interaction: a pharmacokinetic study. Epilepsia. 1984;25:229-233.
73. Sherwin A. Ethosuximide: clinical use. In: Levy R, Mattson R, Meldrum B, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press; 1995: 667-673.
74. Bachmann KA, Schwartz J, Jauregui L, et al. Use of three probes to assess the influence of sex on hepatic drug metabolism. Pharmacology. 1987;35:88-93.
75. Marbury T, Lee C, Perchalski R. Hemodialysis clearance of ethosuximide in patients with chronic renal failure. Am J Hosp Pharm. 1981;38:1757-1760.
76. Marquardt E, Ishisaka D, Batra K, et al. Removal of ethosuximide and phenobarbital by peritoneal dialysis in a child. Clin Pharm. 1992;11:1030-1031.
77. Browne T, Feldman R, Buchanan R. Methsuximide for complex seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983;33:414-418.
78. Dawson G, Brown H, Clark B. Serum phenytoin after ethosuximide. Ann Neurol. 1978;4:583-584.
79. Frantzen E, Hansen J, Hansen O, et al. Phenytoin (Dilantin) intoxication. Acta Neurol Scand. 1967;43:440-446.
80. Rambeck B. Pharmacological interactions of methsuximide with phenobarbital and phenytoin in hospitalized epileptic patients. Epilepsia. 1979; 20:147-156.
81. Smith G, McKauge L, Dubetz D, et al. Factors influencing plasma concentrations of ethosuximide. Clin Pharmacokinet. 1979;4:38-52.
82. Schmidt D. The effect of phenytoin and ethosuximide on primidone metabolism in patients with epilepsy. J Neurol. 1975;209:115-123.
83. Battino D, Avanzini G, Bossi L. Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy. Ther Drug Monit. 1983;5:73-79.
84. Riva R, Albani F, Contin M, et al. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet. 1996;31:470-493.
85. Eadie M, Tyrer J. In: Eadie M, Tyrer J, eds. Anticonvulsant Therapy. Pharmacological Basis and Practice. 2nd ed. Edinburgh: Churchill Livingstone; 1980:211-223.
86. Salke-Kellermann R, May T, Boenigk H. Influence of ethosuximide on valproic acid serum concentrations. Epilepsy Res. 1997;26:345-349.
87. Warren JJ, Benmaman J, Wannamaker B, et al. Kinetics of a carbamazepine-ethosuximide interaction. Clin Pharmacol. 1980;28:646-651.
88. Battino D, Cusi C, Franceschetti S, et al. Ethosuximide plasma concentrations: influence of age and associated concomitant therapy. Clin Pharmacokinet. 1982;7:176-180.
89. Bachmann K, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica. 1993;23:307-315.
90. Giaconne M, Bartoli A, Gatti G, et al. Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 1996;41:575-579.
91. Duncan JS, Patsalos PN, Shorvon SD. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. Epilepsia. 1991;32:101-115.
92. Bourgeois B. Pharmacologic interactions between valproate and other drugs. Am J Med. 1988;84:28-33.
93. Gram L, Wulff K, Rasmussen K, et al. Valproate sodium: a controlled clinical trial including monitoring of drug levels. Epilepsia. 1977;18:141-148.
94. Mattson R, Cramer J. Valproic acid and ethosuximide interaction. Ann Neurol. 1980;7:583-584.
95. Levy R, Koch K. Drug interactions with valproic acid. Drugs. 1982;24:543-556.
96. van Wieringen A, Vrijlandt C. Ethosuximide intoxication caused by interaction with isoniazid. Neurology. 1983;33:1227-1228.
97. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 1997;38: S9-S17.
98. Reinhard J, Reinhard J. Experimental evaluation of anticonvulsants. In: Vida J, ed. Anticonvulsants. New York: Academic Press; 1977:57-111.
99. Woodbury D. Applications to drug evaluations. In: Purpura P, Penry J, Tower D, et al., eds. Experimental Models of Epilepsy: A Manual for The Laboratory Worker. New York: Raven Press; 1972:557-583.
100. Swinyard E, Woodhead J, White H, et al. General principles. Experimental selection, quantification and evaluation of anticonvulsants. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989:85-102.
101. Heller A, Dichter M, Sidman R. Anticonvulsant sensitivity of absence seizures in the tottering mutant mouse. Epilepsia. 1983;25:25-34.
102. Marescaux C, Micheletti G, Vergnes M, et al. A model of chronic spontaneous petit mal-like seizures in the rat: comparison with pentylenetetrazol-induced seizures. Epilepsia. 1984;25:326-331.
103. Sasa M, Ohno Y, Ujihara H. Effects of antiepileptic drugs on absence-like and tonic seizures in the spontaneously epileptic rat, a double mutant rat. Epilepsia. 1988;29:505-513.
104. Godschalk M, Dzoljic M, Bonta I. Antagonism of gamma-hydroxybutyrate-induced hypersynchronization in the ECoG of the rat by anti-petit mal drugs. Neurosci Lett. 1976;3:145-150.
105. Snead OI. Gamma-hydroxybutyrate in the monkey, II: effect of chronic oral anticonvulsant drugs. Neurology. 1978;28:643-648.
106. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
107. Browne TR, Dreifuss FE, Dyken PR, et al. Ethosuximide in the treatment of absence (petit mal) seizures. Neurology. 1975;25:515-524.
108. Sherwin A, Robb P, Lechter M. Improved control of epilepsy by monitoring plasma ethosuximide. Arch Neurol. 1973;28:178-181.
109. Callaghan N, O'Hara J, O'Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol. 1982;24:830-836.
110. Martinovic Z. Comparison of ethosuximide with sodium valproate. In: Parsonage M, Grant R, Craig AW Jr, eds. Advances in Epileptology. XIVth Epilepsy International Symposium. New York: Raven Press; 1983:301-305.
111. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology. 1982;32:157-163.
112. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2003:CD003032.
113. Rowan A, Meijer J, deBeer-Pawlikowski N, et al. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol. 1983;40:797-802.
114. Sherwin A. Ethosuximide: clinical use. In: Levy R, Dreifuss F, Mattson R, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989: 685-698.
115. Guberman A, Cantu-Reyna G, Stuss D, et al. Nonconvulsive generalized status epilepticus: clinical features, neuropsychological testing, and longterm follow-up. Neurology. 1986;36:1284-1291.
116. Browne TR, Dreifuss FE, Penry JK, et al. Clinical and EEG estimates of absence seizure frequency. Arch Neurol. 1983;40:469-472.
117. Roger J, Genton P, Bureau M, et al. Less common epileptic syndromes. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. Philadelphia, PA: Lea & Febiger; 1993:624-635.
118. Farrell K. Secondary generalized epilepsy and Lennox-Gastaut syndrome. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. Philadelphia, PA: Lea & Febiger; 1993:604-613.
119. Serratosa J, Delgado-Escueta A. Juvenile myoclonic epilepsy. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. Philadelphia, PA: Lea & Febiger; 1993:552-570.
120. Wallace S. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147-154.
121. Yasuhara A, Yoshida H, Hatanaka T, et al. Epilepsy with continuous spikewaves during slow sleep and its treatment. Epilepsia. 1991;32:59-62.
122. Zifkin B, Andermann F. Epilepsy with reflex seizures. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. Philadelphia, PA: Lea & Febiger; 1993:614-623.
123. Ames F, Enderstein O. Ictal laughter: a case report with clinical, cinefilm, and EEG observations. J Neurol Neurosurg Psychiatry. 1975;38:11-17.
124. Capovilla G, Beccaria F, Veggoiotti P, et al. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol. 1999;14:395-400.
125. Oguni H, Uehara T, Tanaka T, et al. Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. Neuropediatrics. 1998;29:29-34.
126. Barton ME, Eberle EL, Shannon HE. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol. 2005;521:79-85.
127. Shannon HE, Eberle EL, Peters SC. Comparison of the effects of anticonvulsant drugs with diverse mechanism of action in the formalin test in rats. Neuropharmacology. 2005;48:1012-1020.
128. Todorovic SM, Rastogi AJ, Jevtovic-Todorovic V. Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats. Br J Pharmacol. 2003;140(2):255-260.
129. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109:150-161.
130. Wang G, Thompson SM. Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008;12(28):11959-11969.
131. Dreifuss F. Ethosuximide: toxicity. In: Levy R, Mattson R, Meldrum B, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press; 1995:675-679.
132. Dreifuss F. Ethosuximide: toxicity. In: Levy R, Mattson R, Meldrum B, et al., eds. Antiepileptic Drugs. 3rd ed. New York: Raven Press; 1989: 699-705.
133. Gordon N. Treatment of epilepsy with O-ethylo-methylsuccinimide (P.M. 671). Neurology. 1961;11:266-268.
134. Livingston S, Pauli L, Najimabadi A. Ethosuximide in the treatment of epilepsy. JAMA. 1952;180:104-107.
135. Zimmerman F, Bergemeister B. A new drug for petit mal epilepsy. Neurology. 1958;8:769-776.
136. Goldensohn E, Hardie J, Borea E. Ethosuximide in the treatment of epilepsy. JAMA. 1962;180:840-842.
137. Weinstein A, Allen R. Ethosuximide treatment of petit mal seizures. A study of 87 pediatric patients. Am J Dis Child. 1966;111:63-67.
138. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol. 1992;34:377-395.
139. Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf. 1994;11:114-144.
140. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf. 1996;15:378-393.
141. Guey J, Charles C, Coquery C, et al. Study of psychological effects of ethosuximide (Zarontin) on 25 children suffering from petit mal epilepsy. Epilepsia. 1967;8:129-141.
142. Smith L, Phillips M, Guard H. Psychometric study of children with learning problems and 14-6 positive spike EEG patterns, treated with ethosuximide (Zarontin) and placebo. Arch Dis Child. 1968;43:616-619.
143. Abu-Arafeh I, Wallace S. Unwanted effects of antiepileptic drugs. Dev Med Child Neurol. 1988;30:117-121.
144. Fischer M, Korskjaer G, Pedersen E. Psychotic episodes in Zarontin treatment. Effects and side-effects in 105 patients. Epilepsia. 1965;6:325-334.
145. Cohadon F, Loiseau P, Cohadon S. Results of treatment of certain forms of epilepsy of the petit mal type by ethosuximide. Rev Neurol. 1964;110:201-207.
146. Lairy C. Psychotic signs in epileptics during treatment with ethosuximide. Rev Neurol. 1964;110:225-226.
147. Sato T, Kondo Y, Matsuo T, et al. Clinical experiences of ethosuximide (Zarontin) in therapy-resistant epileptics. Brain Nerve (Tokyo). 1965;17:958-964.
148. Wolf P, Inoue Y. Therapeutic response of absence seizures in patients of an epilepsy clinic for adolescents and adults. J Neurol. 1984;231:225-229.
149. Buchanan R. Ethosuximide: toxicity. In: Woodbury D, Penry J, Schmidt R, eds. Antiepileptic Drugs. New York: Raven Press; 1972:449-454.
150. Heathfield K, Jewesbury E. Treatment of petit mal with ethosuximide. Br Med J. 1961;2:565.
151. Todorov A, Lenn N, Gabor A. Exacerbation of generalized nonconvulsive seizures with ethosuximide therapy. Arch Neurol. 1978;35: 389-391.
152. Uetrecht JP. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev. 1992;24: 299-366.
153. Gibaldi M. Adverse drug effect-reactive metabolites and idiosyncratic drug reactions: part I. Ann Pharmacother. 1992;26:416-421.
154. Glauser TA. Idiosyncratic reactions: new methods of identifying high-risk patients. Epilepsia. 2000;41:S16-S29.
155. Pellock JM. Standard approach to antiepileptic drug treatment in the United States. Epilepsia. 1994;35:S11-S18.
156. Taafe A, O'Brien C. A case of Stevens-Johnson syndrome associated with the anticonvulsants sulthiame and ethosuximide. Br Dent J. 1975;138:172-174.
157. Dabbous IA, Idriss HM. Occurrence of systemic lupus erythematosus in association with ethosuccimide therapy. Case report. J Pediatr. 1970;76:617-620.
158. Alter BP. Systemic lupus erythematosus and ethosuccimide. J Pediatr. 1970;77:1093-1095.
159. Livingston S, Rodriguez H, Greene CA, et al. Systemic lupus erythematosus. Occurrence in association with ethosuximide therapy. JAMA. 1968;203: 731-732.
160. Teoh PC, Chan HL. Lupus-scleroderma syndrome induced by ethosuximide. Arch Dis Child. 1975;50:658-661.
161. Singsen B, Fishman L, Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics. 1976;57:529-534.
162. Cohn R. A neuropathological study of a case of petit mal epilepsy. Electroencephalogr Clin Neurophysiol. 1968;24:282.
163. Kiorboe E, Paludan J, Trolle E, et al. Zarontin (ethosuximide) in the treatment of petit mal and related disorders. Epilepsia. 1964;5:83-89.
164. Kousoulieris E. Granulopenia and thrombocytopenia after ethosuximide. Lancet. 1967;2:310-311.
165. Spittler J. Agranulocytosis due to ethosuximide with a fatal outcome. Klin Paediatr. 1974;186:364-366.
166. Massey GV, Dunn NL, Heckel JL, et al. Aplastic anemia following therapy for absence seizures with ethosuximide [review]. Pediatr Neurol. 1994;11:59-61.
167. Mann L, Habenicht H. Fatal bone marrow aplasia associated with administration of ethosuximide (Zarontin) for petit mal epilepsy. Bull Los Angeles Neurol Soc. 1962;27:173-176.
168. Seip M. Aplastic anemia during ethosuximide medication. Treatment with bolus-methylprednisolone. Acta Paediatr Scand. 1983;72:927-929.
169. Imai T, Okada H, Nanba M, et al. Ethosuximide induced agranulocytosis. Brain Dev. 2003;25:522-524.
170. Ehyai A, Kilroy A, Fenicheal G. Dyskinesia and akathisia induced by ethosuximide. Am J Dis Child. 1978;132:527-528.
171. Kirschberg G. Dyskinesia-an unusual reaction to ethosuximide. Arch Neurol. 1975;32:137-138.
172. Nishiyama J, Matsukura M, Fugimoto S, et al. Reports of 2 cases of autoimmune thyroiditis while receiving anticonvulsant therapy. Eur J Pediatr. 1983;140:116-117.
173. Wassner S, Pennisi A, Malekzadeh M, et al. The adverse effect of anticonvulsant therapy on renal allograft survival. A preliminary report. J Pediatr. 1976;88:134-137.
174. Porter R, Penry J, Dreifuss F. Responsiveness at the onset of spike-wave bursts. Electroencephalogr Clin Neurophysiol. 1973;34:239-245.
175. Sullivan F, McElhatton P. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. Toxicol Appl Pharmacol. 1977; 40:365-378.
176. Bourgeois BF. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia. 1995;36:S1-S7.